The process of reviewing and assessing manuscripts must strictly adhere to the research and publication ethics guidelines recommended by leading organizations, including the Council of Science Editors (CSE, http://www.councilscienceeditors.org/), International Committee of Medical Journal Editors (ICMJE, http://www.icmje.org/), World Association of Medical Editors (WAME, http://www.wame.org/), Korean Association of Medical Journal Editors (KAMJE, https://www.kamje.or.kr/en/main_en), and Committee on Publication Ethics (COPE, http://publicationethics.org/). Instances of plagiarism, duplication, research misconduct, and each ethical issue will be handled according to COPE guidelines, including investigations, retractions, or sanctions, as deemed necessary by the editorial board. Reviewers are responsible for reporting suspected misconduct, and the editorial board may impose sanctions, notify relevant institutions, or publish corrections when warranted.
All research involving human or animal subjects must comply with ethical standards. Studies with human subjects require Institutional Review Board (IRB) approval and adherence to the principles of the Declaration of Helsinki (https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/). Clinical studies that do not meet the Helsinki Declaration guidelines will not be considered for publication. Informed consent must be obtained, and personal identifiers such as names, initials, or other protected healthcare information must not be disclosed. Use of laboratory animals, and the ethical treatment of all experimental animals must conform to the guidelines provided by the Institutional Animal Care and Use Committee (IACUC) or an equivalent body.
All studies involving human subjects must obtain informed consent from participants, and this should be explicitly stated in the manuscript. For case reports or studies with potential privacy concerns, authors must secure additional consent confirming participants' permission to publish the final version, including all photographs, videotapes, and other images (imaging records), text, and data.
IRB approval, along with reference numbers, must also be documented in the Methods section. If ethics approval is waived, this exemption and the granting committee must be detailed in the manuscript. Authors may be required to provide copies of consent forms, IRB approvals, or related documentation upon request by editors or reviewers.
Authors must disclose all potential conflicts of interest that could influence their research or interpretation of data, including financial support, relationships with pharmaceutical or commercial entities, political pressures, or academic issues. These disclosures should be included in the manuscript, even if the authors believe their judgments were unaffected. All sources of funding must be stated in the Acknowledgments section or under a “Conflicts of Interest” subheading, and the role of sponsors in the study design, data analysis, or manuscript preparation should be described. If no conflicts exist, a statement such as “The authors declare no potential conflict of interest." must be included. Editors and reviewers may request additional information or clarification as needed.
According to the guidelines of the ICMJE, authorship should be based on significant contributions to the research, including: 1) substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; 2) drafting the article or revising it critically for important intellectual content; and 3) final approval of the version to be published. 4) Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. All authors must meet these four criteria, and their specific contributions should be disclosed. Individuals who do not meet all criteria should be acknowledged as contributors, not listed as authors. The corresponding author is responsible for communications with the editor and readers, and all authors must approve the final manuscript for publication.
Duplicate publication is defined as “reporting (publishing or attempting to publish) substantially the same work more than once, without attribution of the original source(s)”. Characteristics of reports that are substantially similar include the following: 1) at least one of the authors must be common to all reports (if there are no common authors, it is more likely plagiarism than redundant publication); 2) the subjects or study populations are identical or overlapping; 3) the methodology is nearly the same or very similar; and 4) the results and their interpretation generally vary little, if at all. When submitting a manuscript, authors should include a letter informing the editor of any potential overlap with other already published material or material being evaluated for publication and should also state how the manuscript submitted to the Journal of Korean Dialysis Access (JKDA) differs substantially from other materials. If all or part of your patient population was previously reported, this should be mentioned in the Methods, with citation of the appropriate reference(s). The duplication will be checked using CrossCheck (https://www.ithenticate.com/) before submission. If duplicate publication related to the papers of this journal is detected, the manuscripts will be rejected, the authors will be announced in the journal, and their institutes will be informed. When the journal faces suspected cases of research and publication misconduct, the resolution process will follow the flowchart provided by the Committee on Publication Ethics. The Editorial Board discusses and makes decisions regarding any suspected cases.
It is possible to republish manuscripts if the manuscripts satisfy the conditions of secondary publication of the Recommendations for the Conduct, Reporting, and Publication of Scholarly Work in Medical Journals (ICMJE, https://www.icmje.org) as follows:
- The authors have received approval from the editors of both journals (the editor concerned with the secondary publication must have access to the primary version).
- The priority for the primary publication is respected by a publication interval negotiated by editors of both journals and the authors.
- The paper for secondary publication is intended for a different group of readers; an abbreviated version could be sufficient.
- The secondary version faithfully reflects the data and interpretations of the primary version.
- The secondary version informs readers, peers, and documenting agencies that the paper has been published in whole or in part elsewhere—for example, with a note that might read, “This article is based on a study first reported in the (journal title, with full reference)”—and the secondary version cites the primary reference.
- The title of the secondary publication should indicate that it is a secondary publication (complete or abridged republication or translation) of a primary publication. Of note, the United States National Library of Medicine (NLM) does not consider translations as “republications” and does not cite or index them when the original article was published in a journal that is indexed in MEDLINE.
(1) Registration of Clinical Trial Research
It is recommended that any research that deals with a clinical trial be registered with a primary national clinical trial registration site, such as www.clinicaltrials.gov, https://cris.nih.go.kr/cris/index.jsp, or other sites accredited by the World Health Organization or the International Committee of Medical Journal Editors.
(2) Data Sharing Policy
JKDA accepts the ICMJE Recommendations for data sharing statement policy (http://icmje.org/icmje-recommendations.pdf). Authors may refer to the editorial, JKDA recommends that all submitted manuscripts that report the results of clinical trials adhere to the "Data Sharing Statements for Clinical Trials: A Requirement of the International Committee of Medical Journal Editors" (https://doi.org/10.3346/jkms.2017.32.7.1051).
Copyright policy: JKDA is the official peer-reviewed publication of the Korean Society of Dialysis Access (KSDA). Upon publication of the articles, all the copyrights are transferred to the KSDA.
JKDA is an open access journal and full text PDF files are also available at the official website (https://www.e-jkda.org/). This is an open-access journal distributed under the terms of the Creative Commons Attribution Non-commercial license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited for non-commercial purpose (http://creativecommons.org/licenses/by-nc/4.0/).
A preprint is defined as a version of a scholarly paper that is posted on an openly available platform prior to formal peer review and publication in a peer-reviewed scholarly journal. JKDA allows authors to submit the preprint to the journal. It is not treated as duplicate submissions or duplicate publications. A DOI to that document must be provided so that reviewers and editors can evaluate the preprinted information and compare it with the submitted manuscript. Preprint submissions will be processed through the same peer-review process as usual submissions.
Nov 25, 2024 Vol.7 No.2, pp. 35~54
MinSung Lee, YoonWon Choi, SeonMin Kim, Geo Neul Park, Soo Jeong Choi
JKDA 2024;7: 19-25 https://doi.org/10.56774/jkda24005Jaeseok Kim
JKDA 2024;7: 1-4 https://doi.org/10.56774/jkda24001